Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Crescita TherapeuticsTSX:CTX 20 EV-to-EBITDA is 6.62 as of Aug. 09, 2026, which is 807% above its 10-year median of 0.73. GuruFocus rates TSX:CTX with a GF Score™ of 20/100. The stock has 5 warning signs investors should review. Among 737 Drug Manufacturers companies, Crescita Therapeutics ranks better than 79.24% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Crescita Therapeutics's enterprise value is C$8.50 Mil.
Crescita Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was C$1.28 Mil. Therefore, Crescita Therapeutics's EV-to-EBITDA for today is 6.62.
The historical rank and industry rank for Crescita Therapeutics's EV-to-EBITDA or its related term are showing as below:
TSX:CTX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -4.77 Med: 0.73 Max: 20.23
Current: 6.62
During the past 12 years, the highest EV-to-EBITDA of Crescita Therapeutics was 20.23. The lowest was -4.77. And the median was 0.73.
TSX:CTX's EV-to-EBITDA is ranked better than 79.24% of 737
companies
in the Drug Manufacturers industry
Industry Median: 13.28
vs TSX:CTX: 6.62
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Crescita Therapeutics's PE Ratio (TTM) for today is calculated as:
Crescita Therapeutics's share price for today is C$0.79.
Crescita Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.010.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Crescita Therapeutics EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Crescita Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Crescita Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crescita Therapeutics EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Crescita Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Crescita Therapeutics's EV-to-EBITDA falls into.
Crescita Therapeutics's current Enterprise Value is C$8.50 Mil.
Crescita Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$1.28 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Crescita Therapeutics (TSX:CTX) has a EV-to-EBITDA of 6.62 as of Aug. 09, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Crescita Therapeutics. This is 807% above median its historical median of 0.73. According to the industry distribution chart, Crescita Therapeutics ranks #153 out of 737 companies in the Drug Manufacturers industry, placing it in the top 20.8%.
Is Crescita Therapeutics' EV-to-EBITDA too high?
Crescita Therapeutics' current EV-to-EBITDA of 6.62 is 807% above median its 10-year median of 0.73. The Drug Manufacturers industry median EV-to-EBITDA is 13.28. Crescita Therapeutics' value of 6.62 is 50.2% below this industry median. Based on the distribution chart, Crescita Therapeutics ranks #153 out of 737 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Crescita Therapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Crescita Therapeutics' EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Crescita Therapeutics ranks #153 out of 737 companies for EV-to-EBITDA. This places Crescita Therapeutics in the top 21% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.28. Crescita Therapeutics' value of 6.62 is 50.2% below this benchmark. While the company's 10-year median is 0.73 vs. the industry median of 13.28, Crescita Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.28, based on 737 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Crescita Therapeutics's current EV-to-EBITDA of 6.62 is 50.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Crescita Therapeutics. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Crescita Therapeutics's current EV-to-EBITDA is 6.62, which is 807% above median its own 10-year median of 0.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescita Therapeutics stock overvalued right now?
Crescita Therapeutics (TSX:CTX) has a current EV-to-EBITDA of 6.62. The current EV-to-EBITDA is 6.62, which is 807% above median its 10-year median of 0.73 and 50.2% below the Drug Manufacturers industry median of 13.28. Crescita Therapeutics' overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Crescita Therapeutics (TSX:CTX), the current EV-to-EBITDA is 6.62 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Crescita Therapeutics Inc is a commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The company has three reportable segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The firm generates its revenue from Commercial Skincare Product Sales in Canada followed by USA and Rest of the world.
20GF Score
Get the complete analysis for TSX:CTX
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:CTX has been successfully added to your 
